



PRESS RELEASE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

This is not Crucell's official publication of the provisional or final result of the Exchange Offer in accordance with Swiss takeover laws. Please see that publication for legally relevant information.

Provisional Result of Exchange Offer for Berna Biotech

Leiden, The Netherlands, February 9, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announces today that until the end of the additional acceptance period on February 8, 2006, 37,167,393 Berna shares have been tendered. This represents 96.56% of the issued Berna shares at that date. Subject to certain conditions subsequent, the Exchange Offer will be settled on February 22, 2006.

Crucell N.V. has applied for a listing of the Crucell shares issued for purposes of the exchange offer on Euronext Amsterdam's Eurolist for a first trading day on the settlement date, i.e. on February 22, 2006. In addition, Crucell N.V. has applied for an additional listing of its shares on SWX Swiss Exchange for a first trading day on February 22, 2006.

Crucell N.V. intends to pursue, following settlement, the squeeze-out of the remaining minority shareholdings and to delist Berna Biotech A.G. in connection therewith.

About Crucell

Crucell (Euronext and NASDAQ Exchanges: CRXL) is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The Company's development programs include collaborations with: Sanofi Pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and, GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6 production technology. The Company also licenses its PER.C6 technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands. For more information, please visit www.crucell.com.

About Berna

Berna (Swiss Exchange: BBIN) develops, produces and markets vaccines and immunotherapeutics for private and public markets worldwide. Headquartered in Berne, Switzerland, with subsidiaries in Europe and Korea, Berna is a fully



integrated vaccines company, employing around 700 people. Berna's range of novel and validated proprietary technology platforms support a strong product portfolio. The company markets its core vaccine products in the field of hepatitis B/paediatric, respiratory and travel vaccines and has a broad development pipeline. Development is supported through alliances with academic and commercial partners. Further information on Berna please visit: www.bernabiotech.com.

Restrictions

The offer referred to in this press release is not directly or indirectly being made in any country or jurisdiction, or to such persons, in which or to which such offer would be illegal or otherwise violate applicable law or regulations or which would require Crucell to change the terms or conditions of the offer in any way, to submit an additional application or filing or to perform additional actions in relation to any state, regulatory or legal authorities. It is not intended to extend the offer to any such country or such jurisdiction or to persons in such country or jurisdiction. Documents relating to the offer must neither be directly or indirectly distributed in such countries or jurisdictions nor be sent to such countries or jurisdictions. Such documents must not be used for the purpose of soliciting the purchase of securities of Berna by anyone from such countries or jurisdictions.

The offer referred to in this press release is not being made in or into the United States of America and may only be accepted outside the United States of America, subject to certain exceptions. Accordingly, copies of this press release are not being made available in and should not be mailed or otherwise distributed or sent in, into or from the United States of America, and persons receiving this press release (including custodians, nominees and trustees) must not distribute or send them into or from the United States of America.

This announcement does not constitute an offer of securities for sale in Switzerland, the United States or any other jurisdiction. The securities referred to in this press release may not be offered or sold in the United States or to or for the benefit of US persons (as such term is defined in Regulation S pursuant to the U.S. Securities Act of 1933, as amended (Securities Act)) unless they are registered pursuant to the Securities Act or pursuant to an available exemption therefrom. The issuer of the securities has not registered, and does not intend to register, any of these securities and does not intend to conduct a public offering of securities in the United States.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and Corporate Communications
Tel. +31 (0)71 524 8718
h.suykerbuyk@crucell.com